Redeye provides an update following Neola Medical’s Q1 2025 report. The quarterly figures were in line with our projections, and the company’s clinical validation phase continues to progress according to plan. A key milestone was reached with the successful enrolment of the first patient in the Swedish clinical study. Given the in-line report and absence of any major surprises, we maintain our base case for Neola Medical.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/